Walter Douthat

Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial

Hiddo J.L. Heerspink, Bergur V. Stefánsson, Glenn M. Chertow et al. · Nephrology Dialysis Transplantation · 2019 · 216 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

David C. Wheeler, Bergur V. Stefánsson, Oleksandr Bilchenko et al. · Nephrology Dialysis Transplantation · 2020 · 190 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Increasing access to integrated ESKD care as part of universal health coverage

David C.H. Harris, Simon Davies, Fredric O. Finkelstein et al. · Kidney International · 2019 · 173 citations · Full text

Medicine, Health Policy, Nephrology +16

Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease

Zien Zhou, Meg Jardine, Qiang Li et al. · Stroke · 2021 · 118 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

A single-oral bolus of 100,000 IU of cholecalciferol at hospital admission did not improve outcomes in the COVID-19 disease: the COVID-VIT-D—a randomised multicentre international clinical trial

Jorge B. Cannata‐Andía, Augusto Díaz-Sottolano, Pehuén Fernández et al. · BMC Medicine · 2022 · 69 citations · Full text

Medicine, Pharmacotherapy, Calcium Homeostasis +13